Search

everythinglearnresearchcommunity

for

Search:↓

A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Recombinant Filaggrin-2 microneedles effectively promote hair growth and repair in hair loss.

Sorafenib often causes skin side effects, indicating effective cancer treatment.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.

Some gonadal hormone drugs can block filovirus entry into cells.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Tofacitinib is a promising treatment for children with rheumatic diseases.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.